Actively hiring
Biotechnology
Hedge Funds & Alternative Investments
Venture Capital
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Portfolio
Companies
86
22 of them startups
Hiring now
31
companies with open roles
Its companies, the freshest money firstAll in Startups
KriyatxVenture round $320.8M · 13 mo ago · 2 roles
AlumisVenture round $40M · 2 yr ago · 4 roles
Element BiosciencesSeries D $277M · 2 yr ago · 19 roles
NGM BioVenture round $142M · 2 yr ago
ImageneBioVenture round $42.6M · 3 yr ago
DELFI DiagnosticsVenture round $225M · 4 yr ago · 5 roles
DNAnexusVenture round $200M · 4 yr ago
EverlywellVenture round $75M · 5 yr ago · 8 roles
HealthVerityVenture round $3.8M · 6 yr ago · 17 roles
insitroVenture round $143M · 6 yr ago · 13 roles
Natera115 roles
Cytokinetics73 roles
Hinge Health69 roles
Centessa Pharmaceuticals29 roles
Madrigal Pharmaceuticals26 roles
Ascendis Pharma23 roles
celldex18 roles
GRAIL18 roles
Allogene Therapeutics15 roles
Disc Medicine13 roles
Bicara Therapeutics12 roles
Color11 roles
ConnectiveRx11 roles
Invivyd9 roles
Overview
Foresite Capital is a multi-stage healthcare investment firm backing companies that combine biology and data to transform medicine. It invests across private venture rounds, crossover financings and public equities in biotechnology, medical technology and data-driven healthcare, and also incubates new companies. The firm was founded in 2011 by Jim Tananbaum, a physician and veteran healthcare investor, and is based in the San Francisco Bay Area.
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
San Francisco
United States
HQ
West Hollywood
United States
Regional office
West Hollywood
9200 Sunset Boulevard
Financials
Total raised
$900M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $900M | Details |
